AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease

AstraZenecaAstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates that accumulate in the nerve cells of patients with PD and appear to spread throughout the nervous system during the progression of the disease. These insights support the development of new PD medicines that seek to remove existing pathological alpha-synuclein aggregates, prevent their formation, or stop them from spreading. Such therapies could potentially prevent or delay the onset of PD, or halt or slow its progression.

MEDI1341 is an antibody that is differentiated by its high affinity, high selectivity and reduced effector function (lower interaction with the immune system), which has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies. MEDI1341 is due to enter Phase I clinical trials later this year.

Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development Biotech Unit and Global Business Development at AstraZeneca, said: "Today there are no medicines that can slow or halt the degenerative progress of Parkinson's disease so this remains a large area of unmet medical need. Takeda has an excellent track record in neuroscience research and we are excited to be working together. By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson's disease around the world."

Emiliangelo Ratti, Head, Global CNS Therapeutic Area Unit, Takeda, said: "Despite modest advancements in maintenance therapies, Parkinson's disease continues to represent a devastating diagnosis and a burdensome challenge for therapeutic discovery. Our collaboration with AstraZeneca is a sophisticated one that will enable us to efficiently advance a validated target in a new modality, with the aim of improving the lives of patients."

Contractual and financial considerations
Under the terms of the agreement, AstraZeneca will lead Phase I development while Takeda will lead future clinical development activities. The companies will share equally future development and commercialisation costs for MEDI1341, as well as any future revenues. Takeda will pay AstraZeneca up to $400 million, including initial revenue in 2017 and development and sales milestones thereafter. Additional terms of the agreement are not disclosed.

About Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disease, after Alzheimer's disease.(1) An estimated seven to ten million people worldwide are living with Parkinson's disease. The combined direct and indirect cost of Parkinson's, including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the United States alone.(2)

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

1. https://www.niehs.nih.gov/research/supported/health/neurodegenerative/index.cfm
2. http://www.pdf.org/parkinson_statistics

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]